# A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

> **NCT03668405** · PHASE1 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 18 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Lu AF20513

## Key facts

- **NCT ID:** NCT03668405
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-26
- **Primary completion:** 2019-05-27
- **Final completion:** 2019-05-27
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** New data: The study was terminated based on new efficacy data from another study
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668405, "A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03668405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*